Last reviewed · How we verify
Mitomycin for pyelocalyceal solution
At a glance
| Generic name | Mitomycin for pyelocalyceal solution |
|---|---|
| Also known as | JELMYTO |
| Sponsor | UroGen Pharma Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer (PHASE3)
- In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial (PHASE1, PHASE2)
- Named Patient Program for Mitomycin for Pyelocalyceal Solution
- uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |